MASSY, FRANCE--(Marketwire - April 01, 2011) -
Quantum Genomics (NYSE Euronext Paris: MLQGC) announced today excellent
from regulatory preclinical studies conducted with the product QGC001, the
drug-candidate of a new class of central anti-hypertensive agents,
aminopeptidase A inhibitors (BAPAI):
* Anti-hypertensive activity of QGC001 after oral administration has been
demonstrated in spontaneously hypertensive rats and conscious
hypertensive DOCA-salt rats
* Toxicology, safety pharmacology and pharmacokinetics studies have
demonstrated that QGC001 is well tolerated both in rats and dogs at
doses superior to 50 times the dose showing anti-hypertensive activity
in rats and has a good bioavailability in dog.
Quantum Genomics plans to submit to AFSSAPS in the following weeks, a
trial application in order to initiate a single ascending dose (SAD)
healthy male volunteer subjects and assess the tolerability of a single
QGC001 and its pharmacokinetics parameters in humans.
"Thanks to our academic partners and the financial support of our
Oseo and the National Research Agency (ANR), we completed successfully
preclinical studies required for the Investigational Medicinal Product
We are very confident for the further clinical development of our
compound QGC001 based on the excellent results obtained so far" said
Ségard, President and Chief Executive Officer of Quantum Genomics.
About Quantum Genomics.
QGC is a biotechnology company seeking to develop new therapies in areas
an unmet medical need exists. QGC is presently focused on the treatment of
It will co-develop those products with academic teams and will set up
alliances and commercial partnerships with larger company in order to make
market. Quantum Genomics owns the worldwide exclusive license from Inserm
The company is headquartered in Massy France under the leadership of Lionel
Ségard, supported by a management team of experienced people,
Balavoine (VP Research & Development) and Michel Lepers (VP Business
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Quantum Genomics via Thomson Reuters ONE